Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer

Jiagge, Evelyn; Jibril, Aisha; Chitale, Dhananjay; Bensenhaver, Jessica; Awuah, Baffour; Hoenerhoff, Mark J.; Adjei, Ernest; Bekele, Mahteme; Abebe, Engida; Nathanson, David; Gyan, Kofi K.; Salem, Barbara; Oppong, Joseph K.; Aitpillah, Francis; Kyei, Ishmael; Bonsu, Ernest Osei; Proctor, Erica; Merajver, Sofía D.; Wicha, Max S.; Stark, Azadeh; Newman, Lisa A.

doi:10.1245/s10434-016-5420-z

Cited by 78 publications

(76 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nonsignificant difference in PRR by Census region (P for heterogeneity = .10) may be related to unique immigration patterns of African immigrants to US cities 33 and the heterogeneous composition of national origins in regionally defined, foreign-born populations by Census region (data not shown) or simply unreliable measures owing to small sample sizes. Results from epidemiological studies conducted in Sub-Saharan Africa are not entirely consistent and not directly comparable because of differing analytical methods and variable sample sizes 23,[34][35][36][37][38][39] ; however, preliminary evidence from these studies shows geographical heterogeneity in breast cancer subtype prevalence, with the proportion of triple-negative breast cancer reported to be relatively lower in East Africa (range, 23%-44%) than in West Africa (range, 27%-61%), 38 in accordance with our findings from the corresponding foreign-born black women with breast cancer in the United States.…”

Section: Discussionmentioning

confidence: 99%

Breast cancer subtypes among Eastern‐African–born black women and other black women in the United States

Sung

DeSantis

Fedewa

et al. 2019

Cancer

View full text Add to dashboard Cite

BACKGROUND:A previous study reported that Eastern-African-born black women in the United States had lower prevalence of estrogen receptor-negative breast cancer than those in US-born and Western-African-born black women, among whom the prevalence was similar. It is unknown whether the prevalence of triple-negative breast cancer (negative for estrogen receptor, progesterone receptor, and human epidermal growth factor 2 receptor) among black women in the United States differs similarly by birthplace. METHODS: In the National Program of Cancer Registries and US Cancer Statistics, the authors identified 65,211 non-Hispanic black women who were diagnosed with invasive breast cancer from 2010 through 2015 and were recorded as being born in the United States, East Africa, West Africa, or the Caribbean. The prevalence of triple-negative and hormone receptor-negative breast cancer (negative for estrogen receptor and progesterone receptor) among each group of foreign-born black women was compared with that among US-born black women and was expressed as the adjusted prevalence rate ratio, accounting for sociodemographic and tumor characteristics. Analyses were stratified by Census region, and region-specific estimates were summarized using random-effects meta-analyses. RESULTS: Compared with US-born black women, the prevalence rate ratio of triple-negative breast cancer was 0.92 (95% CI, 0.81-1.04) among Western-African-born, 0.87 (95% CI, 0.78-0.98) among Caribbean-born, and 0.53 (95% CI, 0.37-0.77) among Eastern-African-born black women. Patterns for hormone receptor-negative tumors were generally similar, although the differences between populations were attenuated. The test for heterogeneity by Census region was not significant in any of the comparisons (all P for heterogeneity >.05). CONCLUSIONS: The prevalence of triple-negative breast cancer among black women in the United States varied significantly by birthplace, particularly among Eastern-African-born black women. These findings underscore the importance of considering geographic origin in studies characterizing breast cancer among women of African descent in the United States and elsewhere. Cancer 2019;125:3401-3411.

show abstract

Section: Discussionmentioning

confidence: 99%

Breast cancer subtypes among Eastern‐African–born black women and other black women in the United States

Sung

DeSantis

Fedewa

et al. 2019

Cancer

View full text Add to dashboard Cite

show abstract

“…29-33 The contribution of germline genetic factors is supported by studies demonstrating increased frequency of TNBC among western, sub-Saharan women, a population likely to have shared ancestry with AA women as a consequence of the colonial-era trans-Atlantic slave trade. 29,34-38 …”

Section: Discussionmentioning

confidence: 99%

Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

Importance African American (AA) women have a two-fold higher incidence of breast cancers that are negative for estrogen receptor, progesterone receptor and HER2/neu (triple negative breast cancer, TNBC) compared with White/Caucasian Americans (WA). TNBC likely arises from different pathogenetic pathways compared to non-TNBC, and benign breast disease (BBD) predicts for future non-TNBC. Objective To determine whether AA identity remained associated with TNBC among women with a prior diagnosis of BBD. Design Retrospective analysis; January 1, 1994-December 31, 2005; mean follow-up 10.2 years. Setting Henry Ford Health System in metropolitan Detroit, Michigan; an integrated multihospital, multispecialty health care system. Participants 2,588 AA and 3,566 WA patients age 40-70 years with biopsy-proven BBD diagnosed 1/1/1994 to 12/31/2005. Main Outcome Measures Subsequent breast cancer, stratified by phenotype. Results BBD detection and management were similar for the AA and WA patients. Subsequent breast cancers developed in approximately 4% of AA patients (mean 6.8 years following BBD diagnosis) and WA patients (mean 6.1 years). More than three-quarters of subsequent cancers in each subset were DCIS or Stage I. The 10-year probability estimate for developing TNBC was 0.56% (95% confidence interval 0.32-1.0) for AA versus 0.25% for WA (95% confidence interval 0.12-0.53). Among the 73 AA patients that developed subsequent invasive breast cancer, 24.2% were TNBC compared to 7.4% of the 111 subsequent invasive BC cases (p=0.0125) among the WA patients. Conclusion and Relevance AA identity persisted as a significant risk factor for TNBC in our study, the largest analysis to date of BBD and subsequent breast cancer phenotypes in a diverse patient population managed equitably. This suggests that AA identity is associated with inherent susceptibility for TNBC pathogenetic pathways.

show abstract

“…Nuclear expression of ER or PR proteins and membranous expression of the HER2 staining were detected according to protocols described earlier [31, 32]. In brief, deparaffinized, formalin-fixed tissues, were labeled with monoclonal mouse antibodies for ER and PR proteins (DAKO) [31], and the qualitative, FDA-approved clinical test “HerceptTest (DAKO) for Her2 [32], using automated immunostainer and following the manufacturer’s protocol [31]. Staining interpretation was according to ASCO/CAP guidelines.…”

Section: Methodsmentioning

confidence: 99%

The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion

et al. 2017

View full text Add to dashboard Cite

BackgroundBreast cancer is the most globally diagnosed female cancer, with the triple negative breast cancer (TNBC) being the most aggressive subtype of the disease. In this study we aimed at comparing the effect of BRCA1-IRIS overexpression on the clinico-pathological characteristics in breast cancer patients with TNBC or non-TNBC in the largest comprehensive cancer center in Egypt.MethodsTo reach this goal, we conducted an observational study at the National Cancer Institute (NCI), Cairo University (Cairo, Egypt). The data on all diagnosed breast cancer patients, between 2009 and 2012, were reviewed. BRCA1-IRIS expression measured using real time RT/PCR in these patients’ tumor samples was correlated to tumor characteristics, such as to clinico-pathological features, therapeutic responses, and survival outcomes.Results96 patients were enrolled and of these 45% were TNBC, and 55% were of other subtypes (hereafter, non-TNBC). All patients presented with invasive ductal carcinomas. No significant difference was observed for risk factors, such as age and menopausal status between the TNBC and the non-TNBC groups except after BRCA1-IRIS expression was factored in. The majority of the tumors in both groups were ≤5 cm at surgery (p = 0.013). However, in the TNBC group, ≤5 cm tumors were BRCA1-IRIS-overexpressing, whereas in the non-TNBC group they were BRCA1-IRIS-negative (p = 0.00007). Most of the TNBC patients diagnosed with grade 1 or 2 were BRCA1-IRIS-overexpressing, whereas non-TNBCs were IRIS-negative (p = 0.00035). No statistical significance was measured in patients diagnosed with grade 3 tumors. Statistically significant difference between TNBCs and non-TNBCs and tumor stage with regard to BRCA1-IRIS-overexpression was observed. Presence of axillary lymph node metastases was positively associated with BRCA1-IRIS overexpression in TNBC group, and with BRCA1-IRIS-negative status in the non-TNBC group (p = 0.00009). Relapse after chemotherapy (p < 0.00001), and local recurrence/distant metastasis after surgery (p = 0.0028) were more pronounced in TNBC patients with BRCA1-IRIS-overexpressing tumors compared to non-TNBC patients. Finally, decreased disease-free survival in TNBC/BRCA1-IRIS-overexpressing patients compared to TNBC/BRCA1-IRIS-negative patients, and decreased overall survival in TNBC as well as non-TNBC patients was driven by BRCA1-IRIS overexpression.ConclusionsTNBC/BRCA1-IRIS-overexpressing tumors are more aggressive than TNBC/BRCA1-IRIS-negative or non-TNBC/BRCA1-IRIS-overexpressing or both negative tumors. Further studies are warranted to define whether BRCA1-IRIS drives the early TNBC lesions growth and dissemination and whether it could be used as a diagnostic biomarker and/or therapeutic target for these lesions at an early stage setting.

show abstract

Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer

Cited by 78 publications

References 16 publications

Breast cancer subtypes among Eastern‐African–born black women and other black women in the United States

Breast cancer subtypes among Eastern‐African–born black women and other black women in the United States

Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer

The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion

Contact Info

Product

Resources

About